Articles related to MYELOMA

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to:

Patients with triple-class-exposed relapsed and refractory multiple myeloma have a dismal prognosis. B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) has previously produced profound, long-lasting responses in individuals with multiple myeloma that has relapsed or become resistant to treatment.

By using mass cytometry (CyTOF) analysis, the researchers profiled plasma cells (PCs) and their B cell lymphopoiesis in BM samples from patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma (MM), and active MM in order to better understand the heterogeneity of MM.

In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.

Despite being mostly low-grade, cytokine release syndrome, skin-related events, and dysgeusia were frequent side effects of talquetamab therapy. Patients who had multiple myeloma that was relapsed or resistant after receiving substantial prior treatment had a significant response to talquetamab.

With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.